Alembic Pharmaceuticals Shares Gain Focus Following USFDA Approval for Fingolimod Capsules
Alembic Pharmaceuticals Receives Final USFDA Approval for Fingolimod Capsules
Shares of Alembic Pharmaceuticals are expected to remain in focus on April 27 after the company announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fingolimod Capsules, 0.5 mg. This approval marks a significant milestone for the company, which has been working to expand its product portfolio in the regulated markets.
Fingolimod Capsules, 0.5 mg, are therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg, marketed by Novartis. The approved product is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in patients aged 10 years and above.
With this approval, Alembic Pharmaceuticals now has a cumulative total of 237 ANDA approvals from the USFDA, comprising 219 final approvals and 18 tentative approvals. This achievement highlights the company's commitment to providing high-quality pharmaceutical products to patients in need.
In addition to this approval, Alembic Pharmaceuticals has been expanding its presence in the European market. The company recently incorporated a wholly owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany to explore new business opportunities related to the promotion, sale, and distribution of its pharmaceutical products.
Recent Milestones for Alembic Pharmaceuticals
| Date | Approval |
|---|---|
| April 27 | Fingolimod Capsules, 0.5 mg |
| Earlier this week | Methotrexate Injection USP in multiple dosage formats |
| Total ANDA Approvals (Cumulative) |
Earlier this week, Alembic also received final USFDA approval for its ANDA for Methotrexate Injection USP in multiple dosage formats, further strengthening its product portfolio in the regulated markets. This approval demonstrates the company's ability to deliver high-quality products to patients in need, and we expect Alembic Pharmaceuticals to continue making significant strides in the pharmaceutical industry.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
Investor Takeaway
Investors should expect Alembic Pharmaceuticals' shares to remain in focus following the USFDA approval for Fingolimod Capsules.
More in Market
SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
